Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Total Current Liabilities (2021 - 2025)

Universe Pharmaceuticals' Total Current Liabilities history spans 4 years, with the latest figure at $20.3 million for Q3 2024.

  • For Q3 2024, Total Current Liabilities rose 47.68% year-over-year to $20.3 million; the TTM value through Sep 2024 reached $20.3 million, up 47.68%, while the annual FY2024 figure was $20.3 million, 47.68% up from the prior year.
  • Total Current Liabilities for Q3 2024 was $20.3 million at Universe Pharmaceuticals, up from $13.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $20.3 million in Q3 2024 and bottomed at $11.2 million in Q3 2021.
  • The 4-year median for Total Current Liabilities is $13.4 million (2022), against an average of $14.6 million.
  • The largest annual shift saw Total Current Liabilities grew 5.01% in 2023 before it surged 47.68% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $11.2 million in 2021, then grew by 16.83% to $13.1 million in 2022, then increased by 5.01% to $13.8 million in 2023, then surged by 47.68% to $20.3 million in 2024.
  • Per Business Quant, the three most recent readings for UPC's Total Current Liabilities are $20.3 million (Q3 2024), $13.8 million (Q3 2023), and $13.1 million (Q3 2022).